INTRODUCTION
============

Genital lymphedema (GL) is an uncommon and disabling disease that manifests as enlargement of the genital region resulting from the disturbance of lymphatic drainage. It causes limitations in mobility, voiding, sexual performance, self-hygiene, and social functions. In the United States, GL a most commonly occur as a complication of a malignancy. In contrast, the majority of GL cases in developing nations occur due to infection with *Wuchereria bancrofti* (filariasis) \[[@b1-aps-2019-01123]\].

Based on its etiology, GL can be considered either primary or secondary \[[@b2-aps-2019-01123]\]. In primary lymphedema, the disturbance of lymphatic drainage may be caused by the obstruction, malformation, or underdevelopment (hypoplasia) of various lymphatic vessels, whereas in secondary lymphedema, acquired diseases may contribute to the disruption or obstruction. Primary lymphedema has various subtypes, which remain poorly understood. The condition can manifest at any age. It is also known as Milroy disease if it occurs in infancy, as lymphedema praecox if it arises during adolescence, and as lymphedema tarda when it appears in patients 30 years of age and older.

A diagnosis can be made from the patient's history and physical examination, supported by common imaging techniques such as computed tomography, magnetic resonance imaging, and duplex ultrasonography. Currently, the standard tool to evaluate lymphatic function is radionuclide lymphoscintigraphy. It is relatively noninvasive and enables clinicians to make both qualitative and quantitative analyses \[[@b3-aps-2019-01123]\].

Currently, there is no cure for GL, but it can be managed with early recognition and therapy. The standard of care for GL is complex (also known as combined or complete) physical therapy. Conservative therapy may produce good results, but the effects are temporary without maintenance and continued compression. Although conservative treatments such as decompression are the first-line approach, surgical intervention has been shown to be effective in certain cases \[[@b4-aps-2019-01123]\].

Surgical treatments for GL divided into two categories: physiologic and ablative. Physiologic treatments aim to enhance theanterograde flow of lymph by increasing the drainage capacity, while ablative procedures minimize the severity by conducting excision of the affected areas. It is suggested that physiologic treatments should be performed in the early stages as an effort to conserve lymph drainage prior to the progression of fibrosis and adipose deposition. In contrast, ablative treatments are applicable for any stages of lymphedema \[[@b5-aps-2019-01123],[@b6-aps-2019-01123]\].

Currently, the most frequently performed physiologic surgical treatments are lymphaticovenular anastomosis and vascularized lymph node transfer \[[@b6-aps-2019-01123]\]. It is important to underscore the fundamental difference between the older (lymphovenous) and more recent (lymphaticovenular) procedures. In lymphaticovenular techniques, the surgeon identifies patent residual lymphatic channels and performs an anastomosis to a recipient venule. In contrast, in the lymphovenous technique, a recipient vein is used for the anastomosis.

Ablative procedures aim to remove the edematous tissue in order to promote improved function and hygiene. These operations are indicated when lymphedema has progressed to significant fibrosis and fatty infiltration, resulting in the disturbance of the remaining lymphatic channels \[[@b6-aps-2019-01123],[@b7-aps-2019-01123]\]. Debulking or excision techniques for the management of GL can involve partial or total resection of the skin and the subcutaneous tissue associated with lymphatic drainage. The Charles procedure was proposed as a modification of the debulking procedure in which surgeons excise circumferentially and resurface the defects with split-thickness grafts taken from the excised tissue. The Charles procedure is considered to be the earliest and most radical ablative technique \[[@b8-aps-2019-01123]\]. However, the principles remain pertinent to patients with end-stage lymphedema. For select patients, these techniques can offer significant satisfaction and excellent end results. This study aimed to systematically review studies evaluating available surgical alternatives for the treatment of male GL.

METHODS
=======

Search strategy and screening procedure
---------------------------------------

A comprehensive electronic bibliographic search was performed in May 2019. A gray literature search was not conducted. The electronic databases of PubMed, Scopus, EMBASE, and Cochrane Library were searched using the following medical subject headings (MeSH): "genital lymphedema AND surgical procedure," "scrotal lymphedema AND surgical procedure," and "penile lymphedema AND surgical procedure." Limits applied to the literature search included: "humans," "English," "full-text," and "articles published between 1990 and 2019."

The titles and abstracts of potentially relevant articles were screened and examined. Lists of references from the articles were also examined to find other relevant studies that were not detected through the electronic search.

Data extraction
---------------

The authors reviewed each title and abstract, along with each potentially relevant article. When provided, the following data were extracted: sample population, patient age, etiology, surgical technique(s), early complications, late complications, quality of life, and duration of follow-up. Evaluable studies were analyzed per endpoint.

Quality assessment
------------------

Selected studies were then appraised using the methodological index for non-randomized studies (MINORS), which is a validated instrument used to evaluate the methodological quality of non-randomized surgical studies. Considering the frequent publication of observational studies in surgery, the MINORS score is key in assessing the validity and quality of published data. The MINORS system utilizes an eight-item index (with a global maximum score of 16) for noncomparative studies and a 12-item index (with a global maximum of 24) for comparative studies \[[@b9-aps-2019-01123]\].

RESULTS AND DISCUSSION
======================

Search and screening results
----------------------------

The initial search of PubMed, Scopus, EMBASE, and Cochrane Library using the keywords mentioned above identified 273 relevant studies. After application of the aforementioned limits, only 164 publications remained. Furthermore, 148 studies were excluded after removal of duplicates and screening of the titles and abstracts. Overall, the full texts of 16 articles were examined based on the inclusion and exclusion criteria. Of these, three further articles were excluded: two because the full-text studies were not found and one because it was a conference abstract. A total of 13 studies met the inclusion criteria and were considered eligible for review as described in [Fig. 1](#f1-aps-2019-01123){ref-type="fig"}.

Demographics
------------

The study populations varied in the characteristics of participants and the sample sizes. The number of participants varied from one to 51 patients who underwent surgical intervention. The patients' mean age ranged from 21 to 74.2 years.

The studies reviewed were conducted across the globe, with populations of different ethnic backgrounds. The disease underlying GL also varied among the studies. Most cases of GL were due either to filariasis infection or progression of malignancy. However, four studies described idiopathic GL, as shown in [Table 1](#t1-aps-2019-01123){ref-type="table"}.

Quality of studies
------------------

A total of 13 studies met the inclusion criteria. Nine studies were determined to be high-quality, as illustrated in [Table 2](#t2-aps-2019-01123){ref-type="table"}. The average MINORS score was 12.45 for studies involving excision and 14 for studies involving lymphovenous anastomosis (LVA). The most common reason for a low score was a failure to describe the inclusion criteria. Lymphedema recurrence during follow-up was reported in four studies of excision and in no studies of LVA.

Ablative surgery: Excision and Charles procedure
------------------------------------------------

Excision was the most common surgical intervention found among the included studies. Nine of the reviewed studies illustrated excision procedures to treat GL \[[@b10-aps-2019-01123]-[@b18-aps-2019-01123]\]. In contrast, only two studies described the use of modified Charles procedures \[[@b19-aps-2019-01123],[@b20-aps-2019-01123]\].

In a study by Scaglioni and Uyulmaz \[[@b10-aps-2019-01123]\], a debulking procedure was followed by a split-thickness skin graft from the unaffected upper thigh to cover the entire penile shaft. In 6 months of follow-up, they did not discover any complication or recurrence. In contrast, Torio-Padron et al. \[[@b18-aps-2019-01123]\] reported early complications such as scrotal hematoma (4%) and wound dehiscence (2%) among a total of 51 patients. However, the follow-up duration was not reported clearly.

Among those studies, some early complications such as cellulitis, infection, wound dehiscence, and scrotal hematoma were reported. In addition, Modolin et al. \[[@b19-aps-2019-01123]\], Machol et al. \[[@b15-aps-2019-01123]\], and Salako et al. \[[@b20-aps-2019-01123]\] illustrated recurrent GL rates of 5%, 25%, and 9.1%, respectively. The earliest disease recurrence was reported to occur during the second year of follow-up.

Physiological surgery: LVA
--------------------------

Despite the fact that lymphaticovenular anastomosis has been widely used for treating GL, several conditions may render cases unsuitable for this technique. Mukenge et al. \[[@b21-aps-2019-01123],[@b22-aps-2019-01123]\] was consistent in treating GL with LVA. Most of the patients included in their studies had been treated for a malignancy prior to complaining of GL. In such severe cases of GL, LVA is considered to be a more effective treatment than lymphaticovenular anastomosis, due to the relatively large diameter of the remaining lymph vessels. Mukenge et al. \[[@b21-aps-2019-01123],[@b22-aps-2019-01123]\] performed LVA between the spermatic funiculus lymphatic collectors and the tributary vessels to the spermatic veins. They conducted end-to-side LVA in their first study and performed latero-lateral or termino-lateral LVA 3 years later as part of a follow-up study. No patients experienced recurrence of the disease during 1 year of follow-up. The authors also described the importance of using the proper method to assess the anastomosis patency during follow-up. In this case, they performed this assessment with noninvasive lymphography using an indocyanine green-photodynamic eye infrared system.

Quality of life
---------------

All of the selected studies reported a better quality of life for patients after surgical intervention. Most of the studies evaluated patients' quality of life by assessing mobility, urinary function, sexual function, and scrotal weight, as depicted in [Table 3](#t3-aps-2019-01123){ref-type="table"}. However, the measurement of quality of life was not standardized among those studies and seemed to be based on patients' subjective reports. Most of the studies applied a qualitative approach to follow-up on patients' functional status. One study adapted the Glasgow Benefit Inventory questionnaire as a quantitative tool for assessing quality of life. Torio-Padron et al. \[[@b18-aps-2019-01123]\] found that the patients had improved general function and physical well-being, while the social support that patients received was unchanged. The selected studies' results would be more comparable if they had utilized a consistent measurement system, such as the International Classification of Functioning Disability and Health (developed by the World Health Organization), or if they had used quantitative tools that might allow for easier comparison.

LIMITATIONS
===========

Several limitations were encountered in this systematic review, such as a lack of research investigating surgical interventions for the treatment of GL. This may result from the low prevalence of GL cases. In addition, most of the studies did not mention the stage of GL; therefore, we were unable to make a more objective comparison among the results of the selected studies. Moreover, the lack of quality of life measurement tools for lymphedema also allowed us to draw only a subjective conclusion regarding the selected studies.

CONCLUSION
==========

In general, the quality of the included literature is considered to be fair. Even though surgical intervention might not always prevent the recurrence of lymphedema, all of the patients in these studies were found to have a better subjective quality of life after the procedure. Due to the subjective nature of these results, we recommend that future studies utilize more quantitative methods to assess patients' quality of life. This study could be used as the basis for evidence-based guidelines to be applied in clinical practice for managing male GL.
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###### 

Characteristics of the reviewed studies

  Study                                           Year   Country       No. of subjects   Mean age (yr)   Etiology
  ----------------------------------------------- ------ ------------- ----------------- --------------- ------------------------------------
  Scaglioni et al. \[[@b10-aps-2019-01123]\]      2018   Switzerland   1                 51              Malignancy
  Vives et al. \[[@b11-aps-2019-01123]\]          2016   Colombia      1                 33              Filariasis
  Pastor et al. \[[@b12-aps-2019-01123]\]         2011   USA           1                 39              Epididymitis
  Garaffa et al. \[[@b13-aps-2019-01123]\]        2008   UK            34                46.6            Idiopathic, infection, malignancy
  Halperin et al. \[[@b14-aps-2019-01123]\]       2007   USA           2                 42.5            Idiopathic
  Machol et al. \[[@b15-aps-2019-01123]\]         2014   USA           4                 35              Infection
  Thejeswi et al. \[[@b16-aps-2019-01123]\]       2012   India         1                 54              Filariasis
  Elkiran et al. \[[@b17-aps-2019-01123]\]        2019   Egypt         1                 21              Inflammation
  Torio-Padron et al. \[[@b18-aps-2019-01123]\]   2015   Germany       51                41              Filariasis, malignancy
  Modolin et al. \[[@b19-aps-2019-01123]\]        2006   Brazil        17                50.5            Filariasis, malignancy, congenital
  Salako et al. \[[@b20-aps-2019-01123]\]         2018   Nigeria       11                48.5            Filariasis
  Mukenge et al. \[[@b21-aps-2019-01123]\]        2007   Italy         1                 75              Malignancy
  Mukenge et al. \[[@b22-aps-2019-01123]\]        2011   Italy         5                 74.2            Malignancy

###### 

Quality assessment of the reviewed studies

  Study                                           Aim   Inclusion of consecutive patients   Prospective collection of data   Endpoints appropriate to the aim of the study   Unbiased assessment of the study endpoint   Follow-up period appropriate to the aim of the study   Loss to follow-up \<5%   Prospective calculation of the study size   Adequate control group   Baseline equivalence of groups   Adequate statistical analyses   Total score
  ----------------------------------------------- ----- ----------------------------------- -------------------------------- ----------------------------------------------- ------------------------------------------- ------------------------------------------------------ ------------------------ ------------------------------------------- ------------------------ -------------------------------- ------------------------------- -------------
  Scaglioni et al. \[[@b10-aps-2019-01123]\]      2     0                                   2                                2                                               1                                           2                                                      2                        0                                           0                        0                                0                               11
  Vives et al. \[[@b11-aps-2019-01123]\]          2     1                                   1                                2                                               2                                           1                                                      1                        0                                           0                        0                                0                               10
  Pastor et al. \[[@b12-aps-2019-01123]\]         2     0                                   1                                1                                               1                                           0                                                      0                        0                                           0                        0                                0                               5
  Garaffa et al. \[[@b13-aps-2019-01123]\]        2     2                                   2                                2                                               2                                           2                                                      2                        0                                           0                        0                                2                               16
  Halperin et al. \[[@b14-aps-2019-01123]\]       2     0                                   2                                2                                               2                                           2                                                      2                        0                                           0                        0                                1                               13
  Machol et al. \[[@b15-aps-2019-01123]\]         2     2                                   2                                2                                               2                                           2                                                      2                        0                                           0                        0                                2                               16
  Thejeswi et al. \[[@b16-aps-2019-01123]\]       2     0                                   2                                2                                               2                                           0                                                      0                        0                                           0                        0                                0                               8
  Elkiran et al. \[[@b17-aps-2019-01123]\]        2     0                                   2                                2                                               2                                           2                                                      2                        0                                           0                        0                                0                               12
  Torio-Padron et al. \[[@b18-aps-2019-01123]\]   2     2                                   2                                2                                               2                                           2                                                      2                        0                                           0                        0                                2                               16
  Modolin et al. \[[@b19-aps-2019-01123]\]        2     2                                   2                                2                                               2                                           2                                                      2                        0                                           0                        0                                2                               16
  Salako et al. \[[@b20-aps-2019-01123]\]         2     2                                   2                                2                                               2                                           2                                                      2                        0                                           0                        0                                0                               14
  Mukenge et al. \[[@b21-aps-2019-01123]\]        2     0                                   2                                2                                               2                                           2                                                      2                        0                                           0                        0                                0                               12
  Mukenge et al. \[[@b22-aps-2019-01123]\]        2     2                                   2                                2                                               2                                           2                                                      2                        0                                           0                        0                                2                               16

###### 

Extracted data from the reviewed studies

  Study                                        Site                Technique                                                Follow-up duration   Clinical outcomes                             Quality of life                                                                            
  -------------------------------------------- ------------------- -------------------------------------------------------- -------------------- --------------------------------------------- -------------------------------------------------------------- --------------------------- ----------------------------------------------------------------------------------------
  Scaglioni et al. \[[@b10-aps-2019-01123]\]   Penis and scrotum   Excision                                                 6 mon                None                                          None                                                           NR                          Improved daily activity and penile erection
  Vives et al. \[[@b11-aps-2019-01123]\]       Penis and scrotum   Excision and flaps                                       1 yr 1 mon           None                                          None                                                           NR                          Improved daily activity and sexual function
  Pastor et al. \[[@b12-aps-2019-01123]\]      Scrotum             Excision                                                 NR                   NR                                            NR                                                             NR                          NR
  Garaffa et al. \[[@b13-aps-2019-01123]\]     Penis and scrotum   Penis: local excision, FTSG                              2 yr 3 mon           None                                          Hypertrophic scars, keloids, and contracture (STSG patients)   NR                          Improved daily activity and sexual function
  Scrotum: partial scrotectomy                                                                                                                                                                                                                                                            
  Halperin et al. \[[@b14-aps-2019-01123]\]    Penis and scrotum   Excision and local flaps                                 6 mon                Cellulitis                                    None                                                           NR                          Improved ambulation, sexual function, and hygiene, and could void in standing position
  Machol et al. \[[@b15-aps-2019-01123]\]      Scrotum             Excision and lateral flaps or STSG                       3 yr                 Wound dehiscence, infection                   Recurrence                                                     NR                          Improved penile erection and sexual function
  Thejeswi et al. \[[@b16-aps-2019-01123]\]    Scrotum             Excision, skin flaps                                     NR                   Wound infection                               None                                                           NR                          Improved mobility
  Elkiran et al. \[[@b17-aps-2019-01123]\]     Scrotum             Excision, anterior-posterior flaps                       1 yr                 None                                          None                                                           NR                          Improved daily activity and cosmetic outcomes
  Torio-Padron et al.                          Scrotum             Excision (no flaps or skin grafts)                       NR                   Scrotal hematoma (4%), dehiscence (2%)        Recurrence (10%)                                               Glasgow Benefit Inventory   Improved general function and physical well-being
  Modolin et al. \[[@b19-aps-2019-01123]\]     Penis and scrotum   Modified Charles procedure                               6 mon 6 yr           None                                          1 patient w/ malignancy recurrence                             NR                          Improved ambulation, sexual function, and hygiene, and could void in standing position
  Salako et al. \[[@b20-aps-2019-01123]\]      Scrotum             Modified Charles procedure                               2 yr                 Scrotal hematoma (27.3%), infection (18.2%)   Recurrence (9.1%)                                              NR                          Improved ambulation and could void in standing position
  Mukenge et al. \[[@b21-aps-2019-01123]\]     Scrotum             End-to-side LVA                                          1 yr                 None                                          None                                                           NR                          Improved sexual function
  Mukenge et al. \[[@b22-aps-2019-01123]\]     Scrotum             LVA with latero-lateral or termino-lateral anastomoses   1 yr                 None                                          None                                                           NR                          Improved daily activity and cosmetic outcomes

NR, not reported; FTSG, full-thickness skin graft; STSG, split-thickness skin graft; LVA, lymphovenous anastomosis.

[^1]: This article was presented as an oral presentation at the 23rd Annual Scientific Meeting of the Indonesian Association of Plastic Reconstructive and Aesthetic Surgeons, on July 16--19, 2019, in Banda Aceh, Indonesia (International Meeting).
